A5064646738- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Peptidase Inhibition and Analysis
- Urological Disorders and Treatments
- Tissue Engineering and Regenerative Medicine
- Galectins and Cancer Biology
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- Fibroblast Growth Factor Research
- CNS Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Toxin Mechanisms and Immunotoxins
- Alzheimer's disease research and treatments
- Viral-associated cancers and disorders
- SARS-CoV-2 detection and testing
- Wnt/β-catenin signaling in development and cancer
- Mass Spectrometry Techniques and Applications
- Prostate Cancer Treatment and Research
Peking University Cancer Hospital
2021-2025
Peking University
2021-2025
National Medical Products Administration
2022-2025
Guizhou University
2024
Beijing University of Technology
2024
Guiyang Medical University
2024
Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as first nectin-4 targeting antibody-drug conjugate treating advanced urothelial carcinoma (UC). A PET imaging method to noninvasively quantify expression level would potentially help select patients most likely respond EV predict response.In this study, we designed a bicyclic peptide-based radiotracer 68Ga-N188. Initially, performed preclinical evaluations of...
Malignant glioma highly expresses carbonic anhydrase IX (CAIX). This study aimed to develop [177Lu]Lu-XYIMSR-01, a small-molecule therapeutic agent CAIX, assess its potential for treating malignant glioma. [177Lu]Lu-XYIMSR-01 was synthesized by radiolabeling DOTA-XYIMSR-01 with 177Lu. In vitro assays were conducted evaluate the affinity U87MG tumor cells. The probe injected via tail vein into subcutaneous and orthotopic models micro-SPECT/CT imaging. survival rates of tumor-bearing mice...
Due to the rapid spread of coronavirus disease 2019 (COVID-19), there is an urgent requirement for development additional diagnostic tools further analysis disease. The isolated nanobody Nb11-59 binds severe acute respiratory syndrome 2 (SARS-CoV-2) receptor-binding domain (RBD) with high affinity neutralize virus and block angiotensin-converting enzyme 2- (ACE2-) RBD interaction. Here, we introduce a novel nanobody-based radiotracer named 68Ga-Nb1159. retained showed reliable radiochemical...
This study aimed to develop a novel prognostic index integrating baseline metabolic tumour volume (MTV) along with clinical and pathological parameters for diffuse large B-cell lymphoma (DLBCL).This prospective trial enrolled 289 patients newly diagnosed DLBCL. The predictive value of was compared Ann Arbor staging National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI). We used the concordance (C-index) calibration curve determine its capacity.Multivariate analysis...
Cancer has emerged as a significant threat to human life, and its incidence mortality are increasing rapidly. As clinicians increasingly seek noninvasively investigate tumor phenotypes evaluate functional molecular responses therapy, the combination of diagnostic imaging with targeted therapy is becoming more widely implemented [1]. Targeted radionuclide involves use small molecules, peptides, and/or antibodies carriers for therapeutic radionuclides, these being referred...
<div>Abstract<p>Purpose: Nectin-4 is an emerging biomarker for cancer diagnosis and therapy. Recently, enfortumab vedotin (EV) was approved by the FDA as first nectin-4 targeting antibody-drug conjugate treating advanced urothelial carcinoma. A PET imaging method to non-invasively quantify expression level would potentially help select patients most likely respond EV predict response. Experimental Design: In this study, we designed a bicyclic peptide-based radiotracer 68Ga-N188....
<p>Figure S1. Synthesis of N188. Figure S2. Mass spectrometry characterization N188.Figure S3. SPR S4. Radio-HPLC 68Ga-N188.Figure S5. Stability 68Ga-N188 in serum and normal saline. S6. FITC-N188. S7. S8. Blood routine safety test. S9. Toxicity test 68Ga-N188. S10. Results PET/CT dynamic imaging studies one healthy subject. S11. Pharmacokinetics mouse blood. Figure. S12 with maximum intensity projection (MIP) reconstruction 12 advanced UC patients obtained pathological sections. S13....
<p>Supplementary Methods</p>
<p>40 min full dynamic Total-body PET imaging of healthy volunteers</p>
<p>40 min full dynamic Total-body PET imaging of Patient 1</p>
<p>Figure S1. Synthesis of N188. Figure S2. Mass spectrometry characterization N188.Figure S3. SPR S4. Radio-HPLC 68Ga-N188.Figure S5. Stability 68Ga-N188 in serum and normal saline. S6. FITC-N188. S7. S8. Blood routine safety test. S9. Toxicity test 68Ga-N188. S10. Results PET/CT dynamic imaging studies one healthy subject. S11. Pharmacokinetics mouse blood. Figure. S12 with maximum intensity projection (MIP) reconstruction 12 advanced UC patients obtained pathological sections. S13....
<p>Supplementary Methods</p>
<p>40 min full dynamic Total-body PET imaging of Patient 6</p>
<p>40 min full dynamic Total-body PET imaging of Patient 8</p>
<p>40 min full dynamic Total-body PET imaging of Patient 1</p>
<p>40 min full dynamic Total-body PET imaging of healthy volunteers</p>